Literature DB >> 20535037

Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation.

Barbara Serafini1, Martina Severa, Sandra Columba-Cabezas, Barbara Rosicarelli, Caterina Veroni, Giuseppe Chiappetta, Roberta Magliozzi, Richard Reynolds, Eliana Marina Coccia, Francesca Aloisi.   

Abstract

A cardinal feature of multiple sclerosis (MS) is the persistent intrathecal synthesis of antibodies. Our previous finding that a large fraction of B cells infiltrating the MS brain are infected with Epstein-Barr virus (EBV) raises the possibility that this virus, because of its ability to establish a latent infection in B cells and interfere with their differentiation, contributes to B-cell dysregulation in MS. The aim of this study was to gain further insight into EBV latency programs and their relationship to B-cell activation in the MS brain. Immunohistochemical analysis of postmortem MS brain samples harboring large EBV deposits revealed that most B cells in white matter lesions, meninges, and ectopic B-cell follicles are CD27+ antigen-experienced cells and coexpress latent membrane protein 1 and latent membrane protein 2A, 2 EBV-encoded proteins that provide survival and maturation signals to B cells. By combining laser-capture microdissection with preamplification reverse transcription-polymerase chain reaction techniques, EBV latency transcripts (latent membrane protein 2A, EBV nuclear antigen 1) were detected in all MS brain samples analyzed. We also found that B cell-activating factor of the tumor necrosis factor family is expressed in EBV-infected B cells in acute MS lesions and ectopic B-cell follicles. These findings support a role for EBV infection in B-cell activation in the MS brain and suggest that B cell-activating factor of the tumor necrosis factor family produced by EBV-infected B cells may contribute to this process resulting in viral persistence and, possibly, disruption of B-cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20535037     DOI: 10.1097/NEN.0b013e3181e332ec

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  46 in total

Review 1.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

2.  Neuroimmunology: B cells and variant BAFF in autoimmune disease.

Authors:  Manuel Comabella
Journal:  Nat Rev Neurol       Date:  2017-06-16       Impact factor: 42.937

3.  Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.

Authors:  Michael P Pender; Peter A Csurhes; Corey Smith; Nanette L Douglas; Michelle A Neller; Katherine K Matthews; Leone Beagley; Sweera Rehan; Pauline Crooks; Tracey J Hopkins; Stefan Blum; Kerryn A Green; Zara A Ioannides; Andrew Swayne; Blake T Aftab; Kaye D Hooper; Scott R Burrows; Kate M Thompson; Alan Coulthard; Rajiv Khanna
Journal:  JCI Insight       Date:  2018-11-15

Review 4.  CD46 processing: a means of expression.

Authors:  Siobhan Ni Choileain; Anne L Astier
Journal:  Immunobiology       Date:  2011-07-13       Impact factor: 3.144

Review 5.  Illuminating vitamin D effects on B cells--the multiple sclerosis perspective.

Authors:  Linda Rolf; Anne-Hilde Muris; Raymond Hupperts; Jan Damoiseaux
Journal:  Immunology       Date:  2016-02-02       Impact factor: 7.397

6.  Factors supporting intrathecal humoral responses following viral encephalomyelitis.

Authors:  Timothy W Phares; Cristina P Marques; Stephen A Stohlman; David R Hinton; Cornelia C Bergmann
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

7.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

Review 8.  Human endogenous retroviruses and the nervous system.

Authors:  Renée N Douville; Avindra Nath
Journal:  Handb Clin Neurol       Date:  2014

9.  Interferon-β therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis.

Authors:  Fabiana Rizzo; Elena Giacomini; Rosella Mechelli; Maria Chiara Buscarinu; Marco Salvetti; Martina Severa; Eliana Marina Coccia
Journal:  Immunol Cell Biol       Date:  2016-06-06       Impact factor: 5.126

10.  Antibodies specific for Epstein-Barr virus nuclear antigen-1 cross-react with human heterogeneous nuclear ribonucleoprotein L.

Authors:  J William Lindsey; Samantha L deGannes; Kimberly A Pate; Xiurong Zhao
Journal:  Mol Immunol       Date:  2015-11-28       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.